Format

Send to

Choose Destination
Drug Discov Today. 2005 Aug 1;10(15):1041-7.

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.

Author information

1
Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland. francesco.hofmann@novartis.com

Abstract

Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed.

PMID:
16055020
DOI:
10.1016/S1359-6446(05)03512-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center